Skye Bioscience marks SBI-100 clinical trial progress with new clinical research organization
News release
by
Skye Bioscience Inc
New York
|
February 08, 2023 07:19 AM Eastern Standard Time
Skye Bioscience CEO Punit Dhillon joined Proactive's Natalie Stoberman to share the latest progress on its SBI-100 Ophthalmic Emulsion (OE) clinical trials.
SBI-100 OE, the company's lead program, is focused on developing a treatment for glaucoma, the world's leading cause of irreversible blindness.
Skye Bioscience is a pharmaceutical company unlocking the potential of cannabinoids through the development of its proprietary cannabinoid derivatives to treat diseases with significant unmet needs.
Contact Details
Proactive Investors US
+1 347-449-0879
